Selection and education of patients for inhaled insulin

被引：3

作者：

Bellary S. ^{[1
]}

Barnett A.H. ^{[1
]}

机构：

[1] Undergraduate Centre, Heart of England NHS Foundation Trust, Birmingham B9 5SS, Bordesley Green East

来源：

Current Diabetes Reports | 2007年 / 7卷 / 5期

关键词：

Chronic Obstructive Pulmonary Disease; Hypoglycemia; Oral Agent; Subcutaneous Insulin; Insulin Delivery;

D O I：

10.1007/s11892-007-0059-6

中图分类号：

学科分类号：

摘要：

Inhaled insulin is a recent advance in insulin delivery that promises to be an effective alternative to subcutaneous insulin. Several insulin delivery systems are currently in development and the first of these has been approved for clinical use. Inhaled insulin offers greater flexibility and convenience for patients with diabetes and may be particularly useful in those who are reluctant to initiate or intensify insulin treatment. Although promising, potential concerns remain regarding its long-term effects on lungs. Also, excluding certain groups of patients such as smokers and those with respiratory illnesses will restrict its use at present. Lack of familiarity with the technology, especially relating to dose adjustments and inhaler device, is also likely to present fresh challenges. But, careful selection of patients, education, and continued support from health professionals is vital to ensure success with this new technology. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：363 / 368

页数：5

共 21 条

[1]

Hunt L.M., Valenzuela M.A., Pugh J.A., NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance, Diabetes Care, 20, pp. 292-298, (1997)

[2]

Zamanini A., Newson R.B., Maisey M., Feher M.D., Injection related anxiety in insulin treated diabetes, Diab Res Clin Pract, 46, pp. 239-246, (1999)

[3]

Koro C.E., Bowlin S.J., Bourgeois N., Fedder D.O., Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report, Diabetes Care, 27, pp. 17-20, (2004)

[4]

Owens D.R., Zinman B., Bolli G., Alternative routes of insulin delivery, Diabet Med, 20, pp. 886-898, (2003)

[5]

Laube B.L., The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination, Respir Care, 50, pp. 1161-1176, (2005)

[6]

Quattrin T., Belanger A., Bohannon N.J., Schwartz S.L., Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial, Diabetes Care, 27, pp. 2622-2627, (2004)

[7]

Defronzo R.A., Bergenstal R.M., Cefalu W.T., Et al., Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial, Diabetes Care, 28, pp. 1922-1928, (2005)

[8]

Rosenstock J., Zinman B., Murphy L.J., Et al., Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial, Ann Intern Med, 143, pp. 549-558, (2005)

[9]

Barnett A.H., Dreyer M., Lange P., Serdarevic-Pehar M., An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin, Diabetes Care, 29, pp. 1818-1825, (2006)

[10]

Barnett A.H., Dreyer M., Lange P., Serdarevic-Pehar M., An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea, Diabetes Care, 29, pp. 1282-1287, (2006)

← 1 2 3 →